Mevacor Study Comparing Rx And OTC Use Is Among FDA Panel Suggestions

Merck should conduct a head-to-head comparison study of Mevacor in prescription and over-the-counter settings, Endocrinologic and Metabolic Drugs Advisory Committee member William Tamborlane, MD, said during a review of Merck's OTC switch application for Mevacor.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet